Oxcarbazepine Tablet, Film Coated
Product Images NDC 60687-722

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 60687-722). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150 mg Oxcarbazepine Tablet Blister (150 mg Blister)

Labels for Oxcarbazepine 150 mg film-coated tablets. Each label shows the proprietary and generic name, dosage strength, tablet form, and manufacturer American Health Packaging with their Columbus, Ohio address. Each label also includes a barcode, placeholder text for expiration date, and lot number information. The labels are arranged in two columns on the sheet.*

FDA Label Image

150 mg Oxcarbazepine Tablets Carton (150 mg Carton)

Label for Oxcarbazepine 150 mg film-coated oral tablets, USP. The package contains 100 tablets (10 bottles of 10 tablets each). Distributed by American Health Packaging, Columbus, Ohio. The label includes storage instructions, drug protection advisory, and directions for pharmacists to dispense the medication guide.*

FDA Label Image

300 mg Oxcarbazepine Tablet Blister (300 mg Blister)

Packaging label for Oxcarbazepine Tablet USP 300 mg, film-coated oral tablets. The label includes batch-specific details like expiration date and lot number space, and a barcode. Labeler is American Health Packaging, Columbus, Ohio.*

FDA Label Image

300 mg Oxcarbazepine Tablets Carton (300 mg Carton)

Oxcarbazepine 300 mg film-coated tablets label showing a package of 100 tablets (10 x 10) from American Health Packaging. The label includes drug name, strength, NDC number 60687-722-01, Rx only designation, and dispensing instructions for pharmacists. Storage conditions and manufacturer details are also provided.*

FDA Label Image

600 mg Oxcarbazepine Tablet Blister (600 mg Blister)

Label for Oxcarbazepine 600 mg film-coated tablets by American Health Packaging. The label includes the drug name, strength (600 mg), dosage form, barcode, and placeholder text for expiration date and lot number. Multiple identical labels are shown in a sheet format.*

FDA Label Image

600 mg Oxcarbazepine Tablets Carton (600 mg Carton)

Label for Oxcarbazepine Tablets USP, 600 mg strength, film-coated oral tablets. The package contains 100 tablets (10 blister packs of 10). The label includes the NDC number 60687-733-01, Rx only status, pharmacist dispensing instructions, storage conditions between 20° to 25°C, and distribution information for American Health Packaging, Columbus, Ohio.*

FDA Label Image

Ahp71101

Oxcarbazepine 150 mg film-coated tablet. The oblong, brown tablet is embossed with 'V' on one side and '7 6' split by a score on the other side. This oral tablet is manufactured by American Health Packaging.*

FDA Label Image

Ahp72201

Oxcarbazepine 150 mg film-coated oral tablet, light brown, capsule-shaped with a score line. One side imprinted with "A" and the other side imprinted with "77". Manufactured by American Health Packaging.*

FDA Label Image

Ahp73301

Oxcarbazepine 150 mg film-coated tablet, oral dosage form. The brown, oblong tablet is scored and imprinted on one side with the letter 'V' and on the other side with the numbers '7 8'. Labeled by American Health Packaging.*

FDA Label Image

Figure 1: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure1)

A Kaplan-Meier survival plot showing exit rates over time in days from Day 2 to Day 11 at 8 am, comparing Oxcarbazepine treatment group (solid line) with Placebo group (dotted line). The y-axis represents the exit rate from 0.0 to 1.0. The chart includes a log-rank test p-value: 0.0001.*

FDA Label Image

Figure 2: Kaplan-meier Estimates Of First Seizure Event Rate By Treatment Group (Figure2)

A Kaplan-Meier plot depicting seizure rate over time from first dose to first seizure, comparing treatment groups Oxcarbazepine and placebo. The x-axis shows days, and the y-axis shows seizure rate. The plot includes a log-rank test with a p-value of 0.046, indicating statistical analysis of the difference between groups.*

FDA Label Image

Figure 3: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure3)

A Kaplan-Meier curve comparing exit rates over time in days between two treatment groups labeled HIGH (solid line) and LOW (dashed line). The y-axis represents the exit rate from 0 to 1.0, and the x-axis shows time to exit up to 130 days. A log-rank test reports a p-value of 0.0001, indicating statistical significance between groups.*

FDA Label Image

Figure 4: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure4)

A Kaplan-Meier survival curve chart showing the exit rate over time (days) for two treatment groups labeled HIGH and LOW. The LOW group (dotted line) has a higher exit rate over time compared to the HIGH group (solid line). The chart includes a log-rank test p-value of 0.0001 indicating statistical significance.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of oxcarbazepine, showing the molecular arrangement including two aromatic rings, a seven-membered ring with a ketone group, and an amide functional group attached to a nitrogen atom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.